Uplisting via Share Consolidation
TerrAscend Schedules Shareholder Meeting to Approve Consolidation for U.S. Uplisting
TerrAscend Corp. (TSX: TSND) is asking shareholders to approve a reverse stock split that could clear the way for a landmark uplisting to a major U.S. exchange like NASDAQ or the NYSE, according to Montreal Gazette. The company has scheduled a Special Meeting for August 24, 2026, with a June 30 record date for eligible voters.
The move follows a seismic shift in U.S. drug policy. In April 2026, Acting Attorney General Todd Blanche issued a final order reclassifying FDA-approved and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, according to Ottawa Sun. For the first time, a legal hook exists that could allow plant-touching cannabis companies onto premier U.S. exchanges.
Why TerrAscend Needs a Reverse Stock Split Now
Major U.S. exchanges require a minimum share price of $3.00 to $4.00 for initial listing. TerrAscend's stock was trading under $1.00 CAD in early June 2026. To bridge that gap, the company plans a share consolidation — commonly called a reverse split — likely at a ratio between 1-for-5 and 1-for-10, according to Calgary Sun. This reduces the total number of shares outstanding and pushes the price per share higher.
Executive Chairman Jason Wild framed the vote as inevitable progress. "Uplisting to a major U.S. exchange is no longer a question of if, it is a question of when," Wild said. "This shareholder vote is an important step." Further details will be filed in a management information circular with the SEC and on SEDAR+ ahead of the meeting, according to Shoreline Beacon.
Schedule III Reclassification Opens the Exchange Door
For over a decade, NYSE and NASDAQ blocked plant-touching cannabis companies from listing. The exchanges feared breaking federal anti-money laundering laws while cannabis remained Schedule I. The April 28, 2026 reclassification of medical cannabis to Schedule III changed that calculus, according to Brantford Expositor. NYSE and NASDAQ are now reportedly in active talks with companies like TerrAscend about the path forward.
The reclassification also kills a painful tax rule. Section 280E of the Internal Revenue Code had prevented cannabis companies from deducting normal business expenses. Eliminating that penalty for medical cannabis operators could effectively double free cash flow for companies like TerrAscend. CEO Ziad Ghanem has called the new framework a major balance sheet strengthener, according to Fort McMurray Today.
TerrAscend's Financial Foundation Heading Into the Vote
TerrAscend reported $65.5 million in revenue for Q1 2026, with a 52.8% gross profit margin and a 26.5% adjusted EBITDA margin, according to Chatham Daily News. The company posted $8.7 million in operating cash flow — its 15th consecutive positive quarter — and $7.8 million in free cash flow, its 11th straight positive quarter. That track record strengthens its case to institutional investors who cannot currently buy OTC stocks.
Skeptics Warn the Listing Ban Has Not Been Formally Lifted
Not everyone is convinced the path is clear. Industry analysts note that while a reverse split meets the price requirement, it does not guarantee a listing. NYSE and NASDAQ have not formally lifted their ban on plant-touching operators. Observers suggest the exchanges may wait for the outcome of broader rescheduling hearings — scheduled to begin June 29, 2026 — or for explicit Congressional action, according to Prince George Post.
The April 2026 order also covers only medical cannabis. Adult-use and recreational cannabis technically remains Schedule I. That gap gives exchanges legal cover to delay. TerrAscend became an SEC filer on August 17, 2022, and listed on the TSX on July 4, 2023, according to Woodstock Sentinel Review. It has spent four years building the regulatory groundwork. Whether August 24 marks a turning point depends heavily on decisions outside the company's control.
Sentiment
NeutralPublishers
13
Articles
13
Reach
13
